Ram I Mahato

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8898633/publications.pdf

Version: 2024-02-01

159 9,036 53
papers citations h-index

g-index
9974
citing authors

86

163 all docs 163
docs citations

163 times ranked

#	Article	IF	CITATIONS
1	Development of Biomaterials for Gene Therapy. Molecular Therapy, 2000, 2, 302-317.	8.2	373
2	pH-Sensitive Cationic Polymer Gene Delivery Vehicle:  N-Ac-poly(l-histidine)-graft-poly(l-lysine) Comb Shaped Polymer. Bioconjugate Chemistry, 2000, 11, 637-645.	3.6	363
3	Novel Branched Poly(Ethylenimine)â^'Cholesterol Water-Soluble Lipopolymers for Gene Delivery. Biomacromolecules, 2002, 3, 1197-1207.	5.4	236
4	Recent advances in hepatocellular carcinoma therapy. , 2017, 173, 106-117.		216
5	Water-Soluble Lipopolymer for Gene Delivery. Bioconjugate Chemistry, 2001, 12, 337-345.	3.6	205
6	Cationic lipid-based gene delivery systems: pharmaceutical perspectives. Pharmaceutical Research, 1997, 14, 853-859.	3.5	200
7	Hydrophobization and bioconjugation for enhanced siRNA delivery and targeting. Rna, 2007, 13, 431-456.	3.5	193
8	Extravasation of polymeric nanomedicines across tumor vasculature. Advanced Drug Delivery Reviews, 2011, 63, 623-639.	13.7	172
9	Biological and Biomaterial Approaches for Improved Islet Transplantation. Pharmacological Reviews, 2006, 58, 194-243.	16.0	171
10	Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA. Pharmaceutical Research, 2011, 28, 2996-3015.	3.5	169
11	Biodistribution and Gene Expression of Lipid/Plasmid Complexes after Systemic Administration. Human Gene Therapy, 1998, 9, 2083-2099.	2.7	160
12	Physicochemical and Pharmacokinetic Characteristics of Plasmici DNA/ Cationic Liposome Complexes. Journal of Pharmaceutical Sciences, 1995, 84, 1267-1271.	3.3	152
13	Mesenchymal stem cell and derived exosome as small RNA carrier and Immunomodulator to improve islet transplantation. Journal of Controlled Release, 2016, 238, 166-175.	9.9	140
14	Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials, 2014, 35, 7077-7087.	11.4	137
15	Optimization of factors influencing the transfection efficiency of folate–PEG–folate-graft-polyethylenimine. Journal of Controlled Release, 2002, 79, 255-269.	9.9	131
16	Pharmaceutical Perspectives of Nonviral Gene Therapy. Advances in Genetics, 1999, 41, 95-156.	1.8	126
17	Extravasation of macromolecules. Advanced Drug Delivery Reviews, 1998, 34, 93-108.	13.7	122
18	Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opinion on Drug Delivery, 2010, 7, 1209-1226.	5.0	120

#	Article	IF	CITATIONS
19	RNAi for Treating Hepatitis B Viral Infection. Pharmaceutical Research, 2008, 25, 72-86.	3.5	112
20	Synthesis and Characterization of Amphiphilic Lipopolymers for Micellar Drug Delivery. Biomacromolecules, 2010, 11, 2610-2620.	5.4	112
21	In Vivo Disposition Characteristics of Plasmid DNA Complexed with Cationic Liposomes. Journal of Drug Targeting, 1995, 3, 149-157.	4.4	108
22	Lipid-polymer hybrid nanocarriers for delivering cancer therapeutics. Journal of Controlled Release, 2018, 271, 60-73.	9.9	103
23	Mesenchymal Stem Cell-Based Therapy. Molecular Pharmaceutics, 2013, 10, 77-89.	4.6	101
24	Nonviral Vectors for In Vivo Gene Delivery: Physicochemical and Pharmacokinetic Considerations. Critical Reviews in Therapeutic Drug Carrier Systems, 1997, 14, 40.	2.2	101
25	Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway. PLoS ONE, 2012, 7, e40021.	2.5	99
26	Folate-PEG-Folate-Graft-Polyethylenimine-Based Gene Delivery. Journal of Drug Targeting, 2001, 9, 123-139.	4.4	98
27	MicroRNAs in the pathogenesis and treatment of progressive liver injury in NAFLD and liver fibrosis. Advanced Drug Delivery Reviews, 2018, 129, 54-63.	13.7	98
28	Soluble Biodegradable Polymer-Based Cytokine Gene Delivery for Cancer Treatment. Molecular Therapy, 2000, 2, 121-130.	8.2	94
29	TGF- \hat{l}^21 Gene Silencing for Treating Liver Fibrosis. Molecular Pharmaceutics, 2009, 6, 772-779.	4.6	92
30	Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(I-lysine). Biochemical Pharmacology, 1997, 53, 887-895.	4.4	91
31	Intratumoral Delivery of p2CMVmIL-12 Using Water-Soluble Lipopolymers. Molecular Therapy, 2001, 4, 130-138.	8.2	90
32	Water insoluble and soluble lipids for gene delivery. Advanced Drug Delivery Reviews, 2005, 57, 699-712.	13.7	90
33	Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-l-lactide) block copolymers for drug delivery. Biomaterials, 2010, 31, 2358-2370.	11.4	90
34	Chemosensitization and inhibition of pancreatic cancer stem cellÂproliferation by overexpression of microRNA-205. Cancer Letters, 2017, 402, 1-8.	7.2	88
35	Non-Viral Peptide-Based Approaches to Gene Delivery. Journal of Drug Targeting, 1999, 7, 249-268.	4.4	84
36	Self-Assembling, Amphiphilic Polymer–Gemcitabine Conjugate Shows Enhanced Antitumor Efficacy Against Human Pancreatic Adenocarcinoma. Bioconjugate Chemistry, 2013, 24, 1161-1173.	3.6	84

#	Article	IF	Citations
37	miRNA profiling in pancreatic cancer and restoration of chemosensitivity. Cancer Letters, 2013, 334, 211-220.	7.2	83
38	Targeted Delivery of siRNA to Hepatocytes and Hepatic Stellate Cells by Bioconjugation. Bioconjugate Chemistry, 2010, 21, 2119-2127.	3.6	82
39	Effect of PEGylation on Biodistribution and Gene Silencing of siRNA/Lipid Nanoparticle Complexes. Pharmaceutical Research, 2013, 30, 342-351.	3.5	81
40	Small molecules targeting microRNA for cancer therapy: Promises and obstacles. Journal of Controlled Release, 2015, 219, 237-247.	9.9	80
41	miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies. Advanced Drug Delivery Reviews, 2015, 81, 34-52.	13.7	77
42	Codelivery of Small Molecule Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer. Molecular Pharmaceutics, 2015, 12, 1289-1298.	4.6	74
43	Micellar Delivery of Bicalutamide and Embelin for Treating Prostate Cancer. Pharmaceutical Research, 2009, 26, 2081-92.	3.5	73
44	Vascular Endothelial Growth Factor Gene Delivery for Revascularization in Transplanted Human Islets. Pharmaceutical Research, 2004, 21, 15-25.	3.5	72
45	Doxorubicin and Lapatinib Combination Nanomedicine for Treating Resistant Breast Cancer. Molecular Pharmaceutics, 2014, 11, 2600-2611.	4.6	72
46	Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA. Expert Opinion on Drug Delivery, 2005, 2, 3-28.	5.0	71
47	Involvement of Specific Mechanism in Plasmid DNA Uptake by Mouse Peritoneal Macrophages. Biochemical and Biophysical Research Communications, 1998, 245, 729-733.	2.1	70
48	Challenges and Recent Advances in Medulloblastoma Therapy. Trends in Pharmacological Sciences, 2017, 38, 1061-1084.	8.7	66
49	Cationic lipid and polymer-based gene delivery to human pancreatic islets. Molecular Therapy, 2003, 7, 89-100.	8.2	64
50	MicroRNAs and Drug Resistance in Prostate Cancers. Molecular Pharmaceutics, 2014, 11, 2539-2552.	4.6	63
51	Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis. Advanced Drug Delivery Reviews, 2021, 176, 113888.	13.7	62
52	Disposition characteristics of plasmid DNA in the single-pass rat liver perfusion system. Pharmaceutical Research, 1996, 13, 599-603.	3. 5	60
53	Enhanced Hepatic Uptake and Bioactivity of Type $\hat{l}\pm 1$ (I) Collagen Gene Promoter-Specific Triplex-Forming Oligonucleotides after Conjugation with Cholesterol. Journal of Pharmacology and Experimental Therapeutics, 2006, 317, 797-805.	2.5	60
54	Co-delivery of small molecule hedgehog inhibitor and miRNA for treating liver fibrosis. Biomaterials, 2016, 76, 144-156.	11.4	60

#	Article	IF	Citations
55	Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer. Cancer Research, 2017, 77, 3244-3254.	0.9	60
56	Combination therapy of paclitaxel and cyclopamine polymer-drug conjugates to treat advanced prostate cancer. Nanomedicine: Nanotechnology, Biology, and Medicine, 2017, 13, 391-401.	3.3	56
57	Development of Targeted Delivery Systems for Nucleic Acid Drugs. Journal of Drug Targeting, 1997, 4, 337-357.	4.4	53
58	Dual responsive micelles capable of modulating miRNA-34a to combat taxane resistance in prostate cancer. Biomaterials, 2019, 192, 95-108.	11.4	52
59	Pharmacokinetics and targeted delivery of proteins and genes. Journal of Controlled Release, 1996, 41, 91-97.	9.9	51
60	Control of pharmacokinetic profiles of drugâ€"macromolecule conjugates. Advanced Drug Delivery Reviews, 1996, 19, 377-399.	13.7	49
61	Micellar formulation of indocyanine green for phototherapy of melanoma. Journal of Controlled Release, 2015, 220, 130-140.	9.9	49
62	ROS-Responsive Polymeric Micelles for Triggered Simultaneous Delivery of PLK1 Inhibitor/miR-34a and Effective Synergistic Therapy in Pancreatic Cancer. ACS Applied Materials & Samp; Interfaces, 2019, 11, 14647-14659.	8.0	49
63	Hypoxia-specific gene expression for ischemic disease gene therapy. Advanced Drug Delivery Reviews, 2009, 61, 614-622.	13.7	47
64	Micellar Delivery of Cyclopamine and Gefitinib for Treating Pancreatic Cancer. Molecular Pharmaceutics, 2012, 9, 2350-2357.	4.6	47
65	Nanoparticle-mediated drug delivery for treating melanoma. Nanomedicine, 2015, 10, 2613-2633.	3.3	46
66	Cationic Lipids with Increased DNA Binding Affinity for Nonviral Gene Transfer in Dividing and Nondividing Cells. Bioconjugate Chemistry, 2005, 16, 156-168.	3.6	45
67	Targeted Delivery of a Triplex-Forming Oligonucleotide to Hepatic Stellate Cellsâ€. Biochemistry, 2005, 44, 4466-4476.	2.5	45
68	Third-party Mesenchymal Stem Cells Improved Human Islet Transplantation in a Humanized Diabetic Mouse Model. Molecular Therapy, 2013, 21, 1778-1786.	8.2	45
69	Mesenchymal stem cell-based therapy for type 1 diabetes. Discovery Medicine, 2014, 17, 139-43.	0.5	45
70	Delivery and Targeting of miRNAs for Treating Liver Fibrosis. Pharmaceutical Research, 2015, 32, 341-361.	3.5	43
71	EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. Molecular Pharmaceutics, 2017, 14, 3121-3133.	4. 6	43
72	Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy. Science Advances, 2020, 6, .	10.3	42

#	Article	IF	CITATIONS
73	Biodistribution and Hepatic Uptake of Triplex-Forming Oligonucleotides against Type $\hat{l}\pm 1$ (I) Collagen Gene Promoter in Normal and Fibrotic Rats. Molecular Pharmaceutics, 2005, 2, 206-217.	4.6	41
74	Co-Expression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist Improves Human Islet Survival and Function. Pharmaceutical Research, 2006, 23, 1970-1982.	3.5	41
75	Structural and Formulation Factors Influencing Pyridinium Lipid-Based Gene Transfer. Bioconjugate Chemistry, 2008, 19, 2499-2512.	3.6	41
76	Nanomedicines of Hedgehog Inhibitor and PPAR- \hat{l}^3 Agonist for Treating Liver Fibrosis. Pharmaceutical Research, 2014, 31, 1158-1169.	3.5	41
77	EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. Biomacromolecules, 2016, 17, 301-313.	5.4	41
78	Gene Modulation for Treating Liver Fibrosis. Critical Reviews in Therapeutic Drug Carrier Systems, 2007, 24, 93-146.	2.2	41
79	Site-Specific Delivery of Oligonucleotides to Hepatocytes after Systemic Administration. Bioconjugate Chemistry, 2008, 19, 290-298.	3.6	39
80	Paclitaxel- and lapatinib-loaded lipopolymer micelles overcome multidrug resistance in prostate cancer. Drug Delivery and Translational Research, 2011, 1, 420-428.	5.8	39
81	Attenuation of early liver fibrosis by pharmacological inhibition of smoothened receptor signaling. Journal of Drug Targeting, 2012, 20, 770-782.	4.4	38
82	Nanomedicines for the Treatment of CNS Diseases. Journal of NeuroImmune Pharmacology, 2017, 12, 1-5.	4.1	38
83	Poly(ethylene glycol)-Block-Poly(2-methyl-2-benzoxycarbonyl-propylene Carbonate) Micelles for Rapamycin Delivery: In Vitro Characterization and Biodistribution. Journal of Pharmaceutical Sciences, 2011, 100, 2418-2429.	3.3	37
84	Caspase-3 Gene Silencing for Inhibiting Apoptosis in Insulinoma Cells and Human Islets. Molecular Pharmaceutics, 2008, 5, 1093-1102.	4.6	36
85	Impact of miRNA-mRNA Profiling and Their Correlation on Medulloblastoma Tumorigenesis. Molecular Therapy - Nucleic Acids, 2018, 12, 490-503.	5.1	36
86	HPMA Polymer-Based Site-Specific Delivery of Oligonucleotides to Hepatic Stellate Cells. Bioconjugate Chemistry, 2009, 20, 213-221.	3.6	35
87	Pharmacokinetics and biodistribution of polymeric micelles containing miRNA and small-molecule drug in orthotopic pancreatic tumor-bearing mice. Theranostics, 2018, 8, 4033-4049.	10.0	35
88	Cyclopamine Attenuates Acute Warm Ischemia Reperfusion Injury in Cholestatic Rat Liver: Hope for Marginal Livers. Molecular Pharmaceutics, 2011, 8, 958-968.	4.6	33
89	Design of Hedgehog pathway inhibitors for cancer treatment. Medicinal Research Reviews, 2019, 39, 1137-1204.	10.5	33
90	Uptake Characteristics of Oligonucleotides in the Isolated Rat Liver Perfusion System. Oligonucleotides, 1996, 6, 177-183.	4.3	32

#	Article	IF	Citations
91	Design, Synthesis and Biological Evaluation of novel Hedgehog Inhibitors for treating Pancreatic Cancer. Scientific Reports, 2017, 7, 1665.	3.3	31
92	Novel water insoluble lipoparticulates for gene delivery. Pharmaceutical Research, 2002, 19, 382-390.	3.5	30
93	iNOS Gene Silencing Prevents Inflammatory Cytokine-Induced \hat{I}^2 -Cell Apoptosis. Molecular Pharmaceutics, 2008, 5, 407-417.	4.6	30
94	Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100. Journal of Controlled Release, 2010, 143, 151-158.	9.9	30
95	Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer. Pharmaceutical Research, 2012, 29, 2079-2091.	3.5	30
96	Cholesterol and Morpholine Grafted Cationic Amphiphilic Copolymers for miRNA-34a Delivery. Molecular Pharmaceutics, 2018, 15, 2391-2402.	4.6	30
97	ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice. Journal of Controlled Release, 2020, 323, 463-474.	9.9	30
98	RNA interference for improving the outcome of islet transplantation. Advanced Drug Delivery Reviews, 2011, 63, 47-68.	13.7	29
99	Bioconjugate Therapeutics: Current Progress and Future Perspective. Molecular Pharmaceutics, 2017, 14, 1321-1324.	4.6	28
100	Inhibition of Endogenous Hedgehog Signaling Protects Against Acute Liver Injury After Ischemia Reperfusion. Pharmaceutical Research, 2010, 27, 2492-2504.	3.5	26
101	XIAP Gene Expression Protects \hat{l}^2 -Cells and Human Islets from Apoptotic Cell Death. Molecular Pharmaceutics, 2010, 7, 1655-1666.	4.6	25
102	Mesenchymal Stem Cells as a Gene Delivery Vehicle for Successful Islet Transplantation. Pharmaceutical Research, 2011, 28, 2098-2109.	3.5	25
103	Biodistribution of Self-Assembling Polymer–Gemcitabine Conjugate after Systemic Administration into Orthotopic Pancreatic Tumor Bearing Mice. Molecular Pharmaceutics, 2017, 14, 1365-1372.	4.6	25
104	Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis. Advanced Drug Delivery Reviews, 2021, 173, 394-415.	13.7	25
105	Lactic acid―and carbonateâ€based crosslinked polymeric micelles for drug delivery. Journal of Polymer Science Part A, 2013, 51, 347-362.	2.3	24
106	Receptor-Mediated Hepatic Uptake of M6Pâ^'BSA-Conjugated Triplex-Forming Oligonucleotides in Rats. Bioconjugate Chemistry, 2006, 17, 823-830.	3.6	23
107	Bipartite Adenoviral Vector Encoding hHGF and hIL-1Ra for Improved Human Islet Transplantation. Pharmaceutical Research, 2009, 26, 587-596.	3.5	23
108	Targeted TFO delivery to hepatic stellate cells. Journal of Controlled Release, 2011, 155, 326-330.	9.9	23

#	Article	IF	Citations
109	Organic Nanocarriers for Delivery and Targeting of Therapeutic Agents for Cancer Treatment. Advanced Therapeutics, 2020, 3, 1900136.	3.2	23
110	Nano-carriers for delivery and targeting of active ingredients of Chinese medicine for hepatocellular carcinoma therapy. Materials Today, 2019, 25, 66-87.	14.2	22
111	siRNA pool targeting different sites of human hepatitis B surface antigen efficiently inhibits HBV infection. Journal of Drug Targeting, 2008, 16, 140-148.	4.4	21
112	Micelle Mixtures for Coadministration of Gemcitabine and GDC-0449 To Treat Pancreatic Cancer. Molecular Pharmaceutics, 2016, 13, 1822-1832.	4.6	21
113	Therapeutic Potential of OMe-PS-miR-29b1 for Treating Liver Fibrosis. Molecular Therapy, 2018, 26, 2798-2811.	8.2	21
114	Bipartite Vector Encoding hVEGF and hIL-1Ra for ex Vivo Transduction into Human Islets. Molecular Pharmaceutics, 2009, 6, 274-284.	4.6	20
115	Impact of CYP2C19 polymorphism on the pharmacokinetics of nelfinavir in patients with pancreatic cancer. British Journal of Clinical Pharmacology, 2015, 80, 267-275.	2.4	19
116	Genetically Modified Mesenchymal Stem Cells for Improved Islet Transplantation. Molecular Pharmaceutics, 2011, 8, 1458-1470.	4.6	18
117	GFAP Promoter-Driven RNA Interference on TGF- \hat{l}^21 to Treat Liver Fibrosis. Pharmaceutical Research, 2011, 28, 752-761.	3.5	18
118	Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent. Pharmaceutical Research, 2012, 29, 3064-3074.	3.5	18
119	Coexpression of Vascular Endothelial Growth Factor and Interleukin-1 Receptor Antagonist for Improved Human Islet Survival and Function. Molecular Pharmaceutics, 2007, 4, 199-207.	4.6	17
120	Gene expression and silencing for improved islet transplantation. Journal of Controlled Release, 2009, 140, 262-267.	9.9	17
121	RGD peptideâ€modified adenovirus expressing hepatocyte growth factor and Xâ€linked inhibitor of apoptosis improves islet transplantation. Journal of Gene Medicine, 2011, 13, 658-669.	2.8	17
122	Design of nanocarriers for efficient cellular uptake and endosomal release of small molecule and nucleic acid drugs: learning from virus. Frontiers of Chemical Science and Engineering, 2014, 8, 387-404.	4.4	17
123	LHRH-Conjugated Micelles for Targeted Delivery of Antiandrogen to Treat Advanced Prostate Cancer. Pharmaceutical Research, 2014, 31, 2784-2795.	3.5	17
124	The use of micelles to deliver potential hedgehog pathway inhibitor for the treatment of liver fibrosis. Theranostics, 2019, 9, 7537-7555.	10.0	17
125	Triplex forming oligonucleotides against type $\hat{l}\pm 1$ (I) collagen attenuates liver fibrosis induced by bile duct ligation. Biochemical Pharmacology, 2010, 80, 1718-1726.	4.4	16
126	Pharmacokinetics and Biodistribution of GDC-0449 Loaded Micelles in Normal and Liver Fibrotic Mice. Pharmaceutical Research, 2017, 34, 564-578.	3.5	16

#	Article	IF	Citations
127	Roles of microRNAs in T cell immunity: Implications for strategy development against infectious diseases. Medicinal Research Reviews, 2019, 39, 706-732.	10.5	16
128	Effect of iNOS and NF-κB gene silencing on β-cell survival and function. Journal of Drug Targeting, 2007, 15, 358-369.	4.4	15
129	Nanoparticulate delivery of potent microtubule inhibitor for metastatic melanoma treatment. Journal of Controlled Release, 2019, 309, 231-243.	9.9	15
130	Genetically Modified Human Bone Marrow Derived Mesenchymal Stem Cells for Improving the Outcome of Human Islet Transplantation. PLoS ONE, 2013, 8, e77591.	2.5	14
131	Opportunities and challenges of fatty acid conjugated therapeutics. Chemistry and Physics of Lipids, 2021, 236, 105053.	3.2	14
132	Polymeric nanomedicine for overcoming resistance mechanisms in hedgehog and Myc-amplified medulloblastoma. Biomaterials, 2021, 278, 121138.	11.4	14
133	Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma. Drug Delivery and Translational Research, 2015, 5, 199-208.	5.8	13
134	Self-assembling lisofylline-fatty acid conjugate for effective treatment of diabetes mellitus. Nanomedicine: Nanotechnology, Biology, and Medicine, 2019, 15, 175-187.	3.3	13
135	Role of miRNA and cancer stem cells in chemoresistance and pancreatic cancer treatment. Expert Opinion on Drug Delivery, 2012, 9, 1443-1447.	5.0	12
136	2,2-Bis(hydroxymethyl) propionic acid based cyclic carbonate monomers and their (co)polymers as advanced materials for biomedical applications. Biomaterials, 2021, 275, 120953.	11.4	12
137	siRNA Delivery and Targeting. Molecular Pharmaceutics, 2009, 6, 649-650.	4.6	11
138	miRNAs as targets for cancer treatment: Therapeutics design and delivery. Advanced Drug Delivery Reviews, 2015, 81, v-vi.	13.7	11
139	Co-delivery of siAlox15 and sunitinib for reversing the new-onset of type 1 diabetes in non-obese diabetic mice. Journal of Controlled Release, 2018, 292, 1-12.	9.9	11
140	Activation of dsRNA-Dependent Protein Kinase R by miR-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance. Diabetes, 2021, 70, 710-719.	0.6	11
141	Coadministration of Polymeric Conjugates of Docetaxel and Cyclopamine Synergistically Inhibits Orthotopic Pancreatic Cancer Growth and Metastasis. Pharmaceutical Research, 2018, 35, 17.	3.5	10
142	Polymeric Micellar Delivery of Novel Microtubule Destabilizer and Hedgehog Signaling Inhibitor for Treating Chemoresistant Prostate Cancer. Journal of Pharmacology and Experimental Therapeutics, 2019, 370, 864-875.	2.5	10
143	Biological and Therapeutic Applications of Small RNAs. Pharmaceutical Research, 2011, 28, 2961-2965.	3.5	9
144	Polymer conjugate of a microtubule destabilizer inhibits lung metastatic melanoma. Journal of Controlled Release, 2017, 249, 32-41.	9.9	9

#	Article	IF	Citations
145	Integrating geriatric assessment and genetic profiling to personalize therapy selection in older adults with acute myeloid leukemia. Journal of Geriatric Oncology, 2022, 13, 871-874.	1.0	9
146	Synthesis and Characterization of an Anti-Apoptotic Immunosuppressive Compound for Improving the Outcome of Islet Transplantation. Bioconjugate Chemistry, 2013, 24, 2036-2044.	3.6	7
147	Core-shell nanoparticulate formulation of gemcitabine: lyophilization, stability studies, and in vivo evaluation. Drug Delivery and Translational Research, 2014, 4, 439-451.	5.8	7
148	Synthesis and Characterization of a Novel Mycophenolic Acid–Quinic Acid Conjugate Serving as Immunosuppressant with Decreased Toxicity. Molecular Pharmaceutics, 2015, 12, 4445-4453.	4.6	7
149	Functional similarity of modified cascade impactor to deposit drug particles on cells. International Journal of Pharmaceutics, 2020, 583, 119404.	5.2	5
150	Nanoformulation design and therapeutic potential of a novel tubulin inhibitor in pancreatic cancer. Journal of Controlled Release, 2021, 329, 585-597.	9.9	5
151	Activation of dsRNA-Dependent Protein Kinase R by MicroRNA-378 Sustains Metabolic Inflammation in Hepatic Insulin Resistance. Diabetes, 2021, , db200181.	0.6	5
152	Effect of magnesium stearate surface coating method on the aerosol performance and permeability of micronized fluticasone propionate. International Journal of Pharmaceutics, 2022, 615, 121470.	5.2	4
153	Plasmid-Based Gene Therapy: Opportunities and Challenges Knock at the Millennium. Journal of Drug Targeting, 1999, 7, 241-243.	4.4	2
154	Diabetes associated fibrosis and drug delivery. Advanced Drug Delivery Reviews, 2021, 178, 113968.	13.7	2
155	Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML) Journal of Clinical Oncology, 2021, 39, 7021-7021.	1.6	1
156	Biopharmaceutical Challenges: Pulmonary Delivery of Proteins and Peptides., 0,, 209-242.		1
157	Combining Stem Cells and Genes for Effective Therapeutics. Molecular Pharmaceutics, 2011, 8, 1443-1445.	4.6	0
158	Target cell movement in cardiovascular and malignant diseases. Advanced Drug Delivery Reviews, 2011, 63, 555-557.	13.7	0
159	A Preface for Engineered Biomimetic Tissue Platforms for in Vitro Drug Evaluation. Molecular Pharmaceutics, 2014, 11, 1931-1932.	4.6	0